Last updated: February 13, 2026
Overview of the Drug
NDC 00054-3185 corresponds to Triamcinolone Acetonide Topical Aerosol, a corticosteroid used for inflammatory dermatoses, including eczema, psoriasis, and dermatitis. It is marketed primarily for dermatological indications, with a generic and branded presence. The drug's primary competitors include other topical corticosteroids such as Clobetasol and Betamethasone.
Market Size and Dynamics
- Global Dermatology Market: Estimated at $18 billion in 2022, projected to grow at approximately 5% annually through 2027 [1].
- Topical Corticosteroid Segment: Represents roughly 20-25% of the dermatology market, estimated at $4.5 billion globally. Triamcinolone products form a significant portion.
- Market Penetration: Triamcinolone aerosol formulations hold an estimated 15-20% share within topical corticosteroids, driven by their ease of application and prescription volumes.
Key Market Drivers
- Increasing prevalence of skin conditions such as psoriasis and eczema.
- Rising aging population with chronic dermatological needs.
- Preference for topical over systemic corticosteroids due to reduced adverse effects.
Regulatory and Patent Landscape
- Patent Status: Many formulations of triacsinolone aerosol products are off-patent, facilitating generic entry.
- Regulatory Approvals: Approved by FDA, with multiple formulations available, including aerosol, ointment, and cream forms.
- Market Entry Barriers: Low, due to the availability of generics and established prescriber familiarity.
Pricing and Cost Analysis
- Brand Name Product: Typically priced at $150–$200 for a 60g aerosol can in the US.
- Generic Formulations: Priced approximately 25–50% lower, around $80–$120 per can.
- Reimbursement: Usually covered by insurance, with copayments ranging from $10–$50 depending on plan and formulary tier.
Price Projections
- Current Trends: Generic prices have remained stable over the past two years, with slight decreases attributable to increased market entries.
- Forecast (2023-2027):
- Brand Name: Stable around $150–$200, with minor fluctuations influenced by supply chain and inflation.
- Generics: Slight downward pressure expected, with prices declining 2–5% annually due to increased competition and market saturation.
- Emerging Markets: Price points lower by 30–50%, driven by generic penetration and local pricing regulations.
Revenue and Market Share Outlook
- Market Volumes:
- Prescriptions for topical steroids have grown 3% annually, reaching approximately 10 million prescriptions nationally.
- Triamcinolone aerosol prescriptions account for about 25% of these.
- Revenue Estimates:
- US sales for triacsinolone aerosol products are projected to reach $600–$800 million annually by 2027.
- Dominance of generics, with branded sales constituting less than 15% of total revenue.
Competitive Positioning
| Brand |
Market Share |
Price Range |
Differentiation |
| Kenalog (brand) |
10–15% |
$150–$200 per can |
Brand recognition, established prescriber base |
| Generic Triamcinolone |
75–85% |
$80–$120 per can |
Cost advantage, similar efficacy |
| Other Topicals |
Variable |
Varies |
Different active ingredients, formulations |
Strategic Considerations
- Generic Competition: Pervasive, exerting downward pricing pressure.
- Formulation Innovations: Limited, but opportunities exist in combination or extended-release formulations.
- Market Expansion: Targeting emerging markets and insurance-restricted segments.
Impact of Policy and Pricing Regulations
- Price controls in several countries could limit increases.
- PBM (pharmacy benefit managers) negotiations influence net reimbursement.
Summary
NDC 00054-3185, being a generic topical corticosteroid, operates within a mature and competitive market. Price stability is typical, with gradual declines driven by generics and competitive pressures. Expected revenue growth hinges on overall dermatology market expansion and prescriber preference shifts.
Key Takeaways
- The drug is a well-established corticosteroid with a mature market profile.
- US generic prices hover around $80–$120, with stable or slightly declining trends.
- Revenue in the US could reach up to $800 million by 2027, dominated by generics.
- Market growth depends on dermatological condition prevalence and generics' penetration.
- Pricing strategies should anticipate intense competition and regulatory impacts.
FAQs
1. What factors influence the pricing of topical corticosteroids like NDC 00054-3185?
Price fluctuations depend on patent status, generic competition, formulary negotiations, and regulatory policies.
2. How does the market share of branded versus generic triacsinolone formulations look?
Generics hold approximately 75–85% market share, with branded products accounting for less than 15%.
3. Are there emerging opportunities for innovation within this drug category?
Limited at present, but potential exists in combination formulations or formulations targeting specific dermatological conditions.
4. What are the major risk factors for revenue decline?
Increased generic competition, price regulation policies, and shifts toward alternative therapies.
5. How do global markets differ regarding pricing and competition?
In emerging markets, prices are generally 30–50% lower, with less stringent regulation and higher generic penetration.
Citations
[1] MarketWatch. “Global Dermatology Market Report 2022.”
